Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 1128Carcinoma, Non-Small-Cell Lung 718Neoplasms 545Prostatic Neoplasms 502Colorectal Neoplasms 438Multiple Myeloma 336Lung Neoplasms 309Neoplasm Metastasis 288Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 245Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 171Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 161Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

tebentafusp 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Interventional × Nevus, Blue × Clear all
NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡